New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced ...

Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.

Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist. The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous ...

Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...